Welcome to our dedicated page for Ludwig Enter news (Ticker: LUDG), a resource for investors and traders seeking the latest updates and insights on Ludwig Enter stock.
Ludwig Enterprises, Inc. (LUDG) generates frequent news as it advances its mRNA- and AI-based diagnostics platform and prepares its Revealia™ cancer screening products for broader use. Company updates focus on scientific milestones, clinical research presentations, product development progress, corporate initiatives, and leadership changes, giving investors and observers insight into how its genomics-based strategy is evolving.
Recent press releases highlight the company’s work on non-invasive breast cancer screening using buccal (cheek) cell mRNA combined with machine learning. Ludwig Enterprises has announced abstracts accepted for publication in the Journal of Clinical Oncology and posted on the American Society of Clinical Oncology (ASCO) website, detailing how panels of mRNA biomarkers and algorithms can generate a breast cancer detection signal from cheek swab samples. Other news has covered the introduction and advanced development of Revealia Breast™, a cheek-swab-based breast cancer screening test designed to establish a personalized inflammatory index and risk score.
Beyond clinical data, Ludwig Enterprises’ news flow includes updates on assay optimization and third-party PCR validation for its Revealia™ program, as well as the filing of a provisional patent for a cancer detection method based on a six-mRNA gene combination. The company has also reported the acquisition of intellectual property for an mRNA Neuro Panel and Serotonin Assay, which it links to potential applications in neuroinflammatory and neurological conditions.
Corporate and capital markets developments also appear in LUDG news, including plans to change the corporate name to Revealia, Inc. or Revealia Diagnostics, Inc., intentions to pursue higher-tier listings, and announcements of new executive appointments. For readers tracking LUDG, this news page offers a centralized view of the company’s scientific progress, product pipeline, and strategic direction over time.
Ludwig Enterprises, Inc. (OTC PINK:LUDG) has announced significant corporate initiatives as it prepares to launch Revealia™, its innovative cancer screening test, in 2024. The company plans to change its name to Revealia™, Inc. and apply for OTCQB listing, with aspirations for higher listings like NASDAQ or CBOE in the future. Revealia™ is positioned as the world's most convenient cancer screening test, utilizing a simple mail-order noninvasive cheek swab.
The company has collected over 3000 mRNA samples from multiple medical clinics across the US and employs proprietary machine learning AI technology for continuous statistical updates. CEO Marvin S. Hausman, MD, states that Ludwig has uncovered potentially game-changing mRNA-based genetic signals associated with cancer presence.
Ludwig Enterprises has filed a provisional patent for an mRNA genetic screening technique targeting breast, colon, and bladder cancers. The innovation focuses on identifying and differentiating cancers and assessing treatment effectiveness through mRNA biomarkers. These biomarkers are dynamic genetic signals that can revolutionize cancer diagnostics. The company is leveraging machine learning AI to continuously update statistical models using patient data from over 40 clinics in the U.S. CEO Marvin S. Hausman highlighted the significance of the breakthrough in tapping into the billion-dollar cancer diagnostic market. Cheek cell samples, collected noninvasively, are analyzed to detect these mRNA biomarkers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Ludwig Enter (LUDG)?
What is the market cap of Ludwig Enter (LUDG)?
